ood morning, everyone, and nice to see you again after our weeklong sojourn. Such breaks are always welcome, but, of course, are followed by a serious game of catch-up. To cope, we our back to the usual routine of quaffing cups of stimulation and invite you to join us as we dig in for another busy week. On that note, here is the latest batch of tidbits. Hope you have a successful day and do keep in touch. We enjoy tips and documents …

Lannett continues to raise prices on older, off-patent drugs by large amounts, despite an inquiry from the Justice Department and an investigation by the Connecticut attorney general, the New York Times informs us. And at an industry conference last week, Lannett chief executive Arthur Bedrosian maintained the price-hike business model is not over. One Wall Street analyst called the company the “last of the pricing Mohicans.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.